<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Cellular and molecular interactions (in vitro)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Major effects</th>
    <th>HIV pathogen
     <sup>a</sup>
    </th>
    <th>ARV</th>
    <th>Opioids</th>
    <th>Outcome</th>
    <th>Model system (in vitro)</th>
    <th>Citation(s)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="7">Mixed-Glia</td>
   </tr>
   <tr>
    <td rowspan="2">HIV expression</td>
    <td>HIV</td>
    <td>No</td>
    <td>
     <p>• Dynorphin</p>
     <p>• U50,488</p>
     <p>(KOR agonists)</p>
    </td>
    <td>
     <p>• ↑ HIV-1 expression,</p>
     <p>• Dynorphin (KOR agonist) ↑ TNF-α, IL-6 mRNA and protein</p>
    </td>
    <td>Human fetal neural cells, HIV-infected promonocyte (U1) line</td>
    <td>(Chao et al. 
     <xref ref-type="bibr" rid="CR80">1995</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV
     <sub>SF162</sub>
    </td>
    <td>No</td>
    <td>
     <p>• U50,488</p>
     <p>• U69,593</p>
     <p>• Dynorphin
      <sub>1–17</sub>;
     </p>
     <p>(KOR agonists)</p>
     <p>• Morphine</p>
    </td>
    <td>• KOR agonists ± TNF-α differentially ↓ HIV p24</td>
    <td>Human, primary mixed neurons and glia</td>
    <td>(Chao et al. 
     <xref ref-type="bibr" rid="CR83">1998a</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="2">Chemokines</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ CCL5, CCL2</p>
     <p>• ↑ [Ca
      <sup>2+</sup>]
      <sub>i</sub> (Beclin1 dependent)
     </p>
     <p>• ↓ Autophagy</p>
    </td>
    <td>Mouse, primary mixed glia</td>
    <td>(Lapierre et al. 
     <xref ref-type="bibr" rid="CR269">2018</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV
     <sub>SF162</sub> (R5)
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ HIV-1 Tat-induced LTR expression</p>
     <p>• ↑ CCR5 expression (inhibited by bivalent ligand in astrocytes)</p>
     <p>• ↑ IL-6</p>
     <p>• ↑ CCL5</p>
    </td>
    <td>Human, primary mixed glia</td>
    <td>(El-Hage et al. 
     <xref ref-type="bibr" rid="CR137">2013</xref>)
    </td>
   </tr>
   <tr>
    <td>Glial restricted precursors: survival &amp; MOR, DOR, KOR expression</td>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine (acting via DOR and/or KOR)</td>
    <td>
     <p>• ↑ Caspase-3 activation &amp; ↑ cell death by Tat or morphine via DOR, KOR</p>
     <p>• No opioid-Tat interactions</p>
    </td>
    <td>Mouse, primary glial precursors</td>
    <td>(Buch et al. 
     <xref ref-type="bibr" rid="CR61">2007</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <p>MOR expression in NPCs;</p>
     <p>NPC survival and developmental fate</p>
    </td>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• MOR expressed by subsets of NPCs</p>
     <p>• ↑ Astrocyte and immature glial death</p>
    </td>
    <td>Mouse, primary mixed glia</td>
    <td>(Khurdayan et al. 
     <xref ref-type="bibr" rid="CR234">2004</xref>)
    </td>
   </tr>
   <tr>
    <td>MOR and CCR5 interactions</td>
    <td>Tat
     <sub>1–86</sub> (from HIV
     <sub>IIIB</sub>)
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>• ↓ Neuronal survival via CCR5 activation in glia (rescued by BDNF treatment)</td>
    <td>Mouse, primary neurons and glia</td>
    <td>(Kim et al. 
     <xref ref-type="bibr" rid="CR237">2018</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV infectivity MOR-CCR5 dimerization</td>
    <td>HIV
     <sub>SF162</sub> (R5)
    </td>
    <td>No</td>
    <td>
     <p>Morphine</p>
     <p>CCR5-MOR bivalent ligand 1b</p>
    </td>
    <td>
     <p>• MOR-CCR5 bivalent ligand blocks HIV infection in astroglia, but not microglia, with morphine</p>
     <p>• MOR-CCR5 bivalent ligand blocks the fusion of HIV gp160 and CCR5-CD4-expressing HEK cells</p>
    </td>
    <td>Human, primary astrocytes and microglia; HEK-293T cells</td>
    <td>(Yuan et al. 
     <xref ref-type="bibr" rid="CR557">2013</xref>; Arnatt et al. 
     <xref ref-type="bibr" rid="CR18">2016</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV expression and maturational fate of neurons and astroglia</td>
    <td>HIV
     <sub>BaL</sub> (R5)
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ HIV p24 and ↑ Tat mRNA levels with morphine after 21 days</p>
     <p>• ↓ Proliferation of neural progenitors; ↑ astroglial and ↑ neuronal differentiation</p>
    </td>
    <td>Human, neural progenitors</td>
    <td>(Balinang et al. 
     <xref ref-type="bibr" rid="CR25">2017</xref>)
    </td>
   </tr>
   <tr>
    <td colspan="7">Astrocytes</td>
   </tr>
   <tr>
    <td>HIV expression</td>
    <td>HIV
     <sub>SF162</sub> (R5)
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ HIV p24</p>
     <p>• ↑ CCL2</p>
    </td>
    <td>Human, primary astrocytes</td>
    <td>(Rodriguez et al. 
     <xref ref-type="bibr" rid="CR433">2017</xref>)
    </td>
   </tr>
   <tr>
    <td>Toll-like receptor (TLR) expression/function</td>
    <td>
     <p>• Tat
      <sub>1–72</sub>
     </p>
     <p>• gp120</p>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ TLR2 with Tat, Tat + morphine, gp120</p>
     <p>• ↓ TLR9 with Tat, morphine, gp120</p>
    </td>
    <td>Mouse, primary astrocytes</td>
    <td>(El-Hage et al. 
     <xref ref-type="bibr" rid="CR135">2011a</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="6">Chemokines</td>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ CCL5, CCL2</p>
     <p>• ↑ IL-6</p>
     <p>• ↑ [Ca
      <sup>2+</sup>]
      <sub>i</sub>
     </p>
    </td>
    <td>Mouse, primary astrocytes</td>
    <td>(El-Hage et al. 
     <xref ref-type="bibr" rid="CR130">2005</xref>)
    </td>
   </tr>
   <tr>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ CCL2</p>
     <p>• ↑ CCL5</p>
     <p>• ↑ Microglial migration</p>
    </td>
    <td>Mouse, primary astrocytes</td>
    <td>(El-Hage et al. 
     <xref ref-type="bibr" rid="CR131">2006a</xref>)
    </td>
   </tr>
   <tr>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ CCL2, ↑ IL-6, ↑ TNF-α</p>
     <p>• ↑ [Ca
      <sup>2+</sup>]
      <sub>i</sub>
     </p>
     <p>• ↑ NF-κB trafficking and transcription</p>
     <p>• No interaction / acceleration with morphine</p>
    </td>
    <td>Mouse, primary astrocytes</td>
    <td>(El-Hage et al. 
     <xref ref-type="bibr" rid="CR134">2008b</xref>)
    </td>
   </tr>
   <tr>
    <td>Tat</td>
    <td>No</td>
    <td>
     <p>• U50,488 (KOR agonist)</p>
     <p>• Nor-BNI (KOR antagonist)</p>
    </td>
    <td>
     <p>• U50,488 ↓ CCL2</p>
     <p>• U50,488 ↓ NF-κB</p>
    </td>
    <td>Human, primary astrocytes</td>
    <td>(Sheng et al. 
     <xref ref-type="bibr" rid="CR464">2003</xref>)
    </td>
   </tr>
   <tr>
    <td>N/A</td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ CCR5, CCR3, CXCR2</p>
     <p>• ↓ IL-8, CCL4</p>
    </td>
    <td>Human, astrocytoma U87 cell line, primary astrocytes</td>
    <td>(Mahajan et al. 
     <xref ref-type="bibr" rid="CR301">2002</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <p>• Tat
      <sub>1–86</sub>
     </p>
     <p>• gp120
      <sub>IIIB</sub>
     </p>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>Regional differences in cytokine and ROS production —differed for each insult</td>
    <td>Mouse, primary astrocytes</td>
    <td>(Fitting et al. 
     <xref ref-type="bibr" rid="CR159">2010a</xref>)
    </td>
   </tr>
   <tr>
    <td>Oxidative stress / damage</td>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>
     <p>• DPDPE</p>
     <p>• SNC-80</p>
     <p>(DOR agonists)</p>
    </td>
    <td>DOR agonists ↓ Tat-induced oxidative stress</td>
    <td>Human derived brain cell line (SK-N-SH)</td>
    <td>(Wallace et al. 
     <xref ref-type="bibr" rid="CR533">2006</xref>)
    </td>
   </tr>
   <tr>
    <td>Inflammation, maturation /plasticity</td>
    <td>
     <p>• Tat
      <sub>86</sub>
     </p>
     <p>• Tat
      <sub>101</sub>
     </p>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>↓ β-catenin signaling and variably decreases 
     <italic>TrkB</italic>, 
     <italic>BDNF</italic>, and 
     <italic>NLRP1</italic> mRNA in fetal astrocytes 
     <sup>b</sup>
    </td>
    <td>Human, U87MG and fetal astrocytes</td>
    <td>(Chen et al. 
     <xref ref-type="bibr" rid="CR91">2020</xref>)
    </td>
   </tr>
   <tr>
    <td colspan="7">Microglia</td>
   </tr>
   <tr>
    <td rowspan="6">HIV replication</td>
    <td>HIV
     <sub>SF162</sub> (R5)
    </td>
    <td>No</td>
    <td>
     <p>• Endomorphin-1</p>
     <p>• Endomorphin-2</p>
     <p>(MOR agonists)</p>
    </td>
    <td>
     <p>• ↑ HIV p24 with endomorphin-1, but not endomorphin-2</p>
     <p>• Endomorphin-1 acts via MOR, but not DOR / KOR</p>
    </td>
    <td>Human, primary microglia</td>
    <td>(Peterson et al. 
     <xref ref-type="bibr" rid="CR396">1999</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV
     <sub>SF162</sub> (R5)
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>↑ HIV p24</td>
    <td>Human, primary microglia</td>
    <td>(El-Hage et al. 
     <xref ref-type="bibr" rid="CR138">2014</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV
     <sub>SF162</sub> (R5)
    </td>
    <td>No</td>
    <td>
     <p>• U50,488; U69,593 (KOR agonists)</p>
     <p>• Dynorphin A
      <sub>l-13</sub>
     </p>
    </td>
    <td>↓ HIV p24</td>
    <td>Human, primary microglia</td>
    <td>(Chao et al. 
     <xref ref-type="bibr" rid="CR82">1996b</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <p>• HIV
      <sub>JR-FL</sub> (R5)
     </p>
     <p>• gp120</p>
    </td>
    <td>No</td>
    <td>β-endorphin</td>
    <td>
     <p>• ↑ HIV expression</p>
     <p>• ↑ HIV p24 (14-day post infection)</p>
     <p>• gp120 ↑ IL-1, TNF, IL-6</p>
    </td>
    <td>Human, fetal microglia</td>
    <td>(Sundar et al. 
     <xref ref-type="bibr" rid="CR493">1995</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV
     <sub>SF162</sub>
    </td>
    <td>No</td>
    <td>
     <p>• 8-CAC, U50,488 (KOR agonists)</p>
     <p>• Cocaine</p>
    </td>
    <td>
     <p>• KOR agonist ↓ p24; blocked by KOR antagonists</p>
     <p>• KOR agonist negates cocaine-induced ↑ HIV</p>
    </td>
    <td>Human, fetal brain microglia</td>
    <td>(Gekker et al. 
     <xref ref-type="bibr" rid="CR173">2004</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV
     <sub>SF162</sub>
    </td>
    <td>No</td>
    <td>
     <p>
      <italic>OPRL1</italic> antisense
     </p>
     <p>Nociceptin / orphanin FQ (OPRL1 agonist)</p>
    </td>
    <td>
     <p>• 
      <italic>OPRL1</italic> antisense (
      <italic>and sense</italic>) ↓ p24
     </p>
     <p>• Nociceptin, no effect on p24</p>
    </td>
    <td>Human, fetal brain microglia and mixed neurons/glia</td>
    <td>(Chao et al. 
     <xref ref-type="bibr" rid="CR84">1998b</xref>)
    </td>
   </tr>
   <tr>
    <td>HIV expression</td>
    <td>
     <p>• HIV
      <sub>SF162</sub>
     </p>
     <p>• Tat</p>
    </td>
    <td>ZDV</td>
    <td>U50,488 (KOR agonist)</td>
    <td>
     <p>• ↓ p24 on day 14 with U50,488</p>
     <p>• ↓ Neurotoxicity (U50,488)</p>
     <p>• ↓ Quinolinate by microglia</p>
    </td>
    <td>Human, fetal microglia and neural cells</td>
    <td>(Chao et al. 
     <xref ref-type="bibr" rid="CR85">2000</xref>)
    </td>
   </tr>
   <tr>
    <td>Chemokines and Cytokines</td>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ CCR5</p>
     <p>• ↑ CD11b, ↑ CD40</p>
     <p>• ↑ TNF-α, ↑ IL-6, ↑ IP-10</p>
     <p>• ↑ iNOS</p>
    </td>
    <td>Mouse, BV-2 and primary microglia</td>
    <td>(Bokhari et al. 
     <xref ref-type="bibr" rid="CR48">2009</xref>)
    </td>
   </tr>
   <tr>
    <td>MOR signaling</td>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ MOR (intracellular)</p>
     <p>• ↑ MOR mRNA</p>
    </td>
    <td>Mouse, N9 and primary microglia</td>
    <td>(Turchan-Cholewo et al. 
     <xref ref-type="bibr" rid="CR514">2008</xref>)
    </td>
   </tr>
   <tr>
    <td>Oxidative Stress</td>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ ROS [O
      <sub>2</sub>
      <sup>−</sup> (DHE), ↑ HO
      <sub>2</sub>
      <sup>•</sup>, H
      <sub>2</sub>O
      <sub>2</sub> (DCF)]
     </p>
     <p>• ↑ Protein carbonyls</p>
    </td>
    <td>Mouse, N9 and primary microglia</td>
    <td>(Turchan-Cholewo et al. 
     <xref ref-type="bibr" rid="CR515">2009</xref>)
    </td>
   </tr>
   <tr>
    <td>Glutamate release</td>
    <td>Tat
     <sub>1–72</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>↑ Glutamate release via ↑ x
     <sub>c</sub>
     <sup>−</sup> cystine-glutamate antiporter expression/function
    </td>
    <td>Mouse, primary microglia</td>
    <td>(Gupta et al. 
     <xref ref-type="bibr" rid="CR195">2010</xref>)
    </td>
   </tr>
   <tr>
    <td colspan="7">Neurons</td>
   </tr>
   <tr>
    <td>HIV expression</td>
    <td>HIV</td>
    <td>No</td>
    <td>Morphine</td>
    <td>↑ HIV expression</td>
    <td>Human derived, SH-SY5Y neuroblastoma cells</td>
    <td>(Squinto et al. 
     <xref ref-type="bibr" rid="CR479">1990</xref>)
    </td>
   </tr>
   <tr>
    <td>Homeostasis and Injury</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ [Ca
      <sup>2+</sup>]
      <sub>i,</sub>
     </p>
     <p>• ↑ [Na
      <sup>+</sup>]
      <sub>i</sub>
     </p>
     <p>• ↓ Δ
      <sub>Ψm</sub> (mitochondrial) instability
     </p>
     <p>• ↑ Dendritic degeneration</p>
    </td>
    <td>Mouse, primary neurons</td>
    <td>(Fitting et al. 
     <xref ref-type="bibr" rid="CR162">2014a</xref>)
    </td>
   </tr>
   <tr>
    <td>Mitochondrial inner membrane potential and ROS</td>
    <td>
     <p>• Tat
      <sub>1–86</sub>, Tat
      <sub>1–72</sub>
     </p>
     <p>• gp120</p>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>↑ Δ
     <sub>Ψm</sub> instability and oxidative stress ↑ with Tat + morphine, ↑ neuroprotection with allopregnanolone
    </td>
    <td>Human, primary neurons ; mouse, striatal medium spiny neurons; mouse, striatal medium spiny neurons, SH-SY5Y neuroblastoma cells</td>
    <td>(Turchan-Cholewo et al. 
     <xref ref-type="bibr" rid="CR513">2006</xref>; Paris et al. 
     <xref ref-type="bibr" rid="CR378">2020</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="3">Neuronal survival</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↓ Neuronal survival from Tat + morphine and ↓ glial CX
      <sub>3</sub>CL1 rescued by CX
      <sub>3</sub>CL
     </p>
     <p>• CX
      <sub>3</sub>CL1 (fractalkine) regulates microglial motility
     </p>
    </td>
    <td>Mouse, primary neurons and mixed glia</td>
    <td>(Suzuki et al. 
     <xref ref-type="bibr" rid="CR496">2011</xref>)
    </td>
   </tr>
   <tr>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↓ Proliferation</p>
     <p>• ↑ ERK1/2 activation</p>
     <p>• ↑ p53 and p21</p>
     <p>• ↓ Cyclin D1 and Akt levels</p>
    </td>
    <td>Human, neuronal precursors</td>
    <td>(Malik et al. 
     <xref ref-type="bibr" rid="CR305">2014</xref>)
    </td>
   </tr>
   <tr>
    <td>Tat
     <sub>1–72</sub>, Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↓ Neuronal survival</p>
     <p>• ↑ Neuronal survival with ibudilast (AV411) (inhibiting glial NF-κB blocks Tat ± morphine neurotoxicity)</p>
    </td>
    <td>Mouse, primary neurons and mixed glia</td>
    <td>(Gurwell et al. 
     <xref ref-type="bibr" rid="CR197">2001</xref>; El-Hage et al. 
     <xref ref-type="bibr" rid="CR138">2014</xref>)
    </td>
   </tr>
   <tr>
    <td colspan="7">White matter/oligodendroglial pathology</td>
   </tr>
   <tr>
    <td>Changes in OL survival and morphology</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine (25 mg pellet, 7 days); morphine (in vitro)</td>
    <td>
     <p>• ↑ Degeneration of OLs</p>
     <p>• ↑ TUNEL reactivity</p>
     <p>• ↑ Caspase-3 activation</p>
    </td>
    <td>Mouse, Tat tg; primary OLs</td>
    <td>(Hauser et al. 
     <xref ref-type="bibr" rid="CR208">2009</xref>)
    </td>
   </tr>
   <tr>
    <td colspan="7">Blood-brain barrier and the neurovascular unit</td>
   </tr>
   <tr>
    <td>BBB model integrity and function</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↑ TNF-α</p>
     <p>• ↑ IL-8</p>
     <p>• ↓TEER</p>
     <p>• ↑ JAM-2 expression</p>
     <p>• ↑ Monocyte transmigration with CCL5</p>
    </td>
    <td>Human, using primary BMVEC and primary astrocytes</td>
    <td>(Mahajan et al. 
     <xref ref-type="bibr" rid="CR303">2008</xref>)
    </td>
   </tr>
   <tr>
    <td>ARV accumulation</td>
    <td>Tat
     <sub>1–86</sub>
    </td>
    <td>
     <p>DTG</p>
     <p>FTC</p>
     <p>TFV</p>
    </td>
    <td>Morphine</td>
    <td>• ↓ Intracellular ARV concentrations</td>
    <td>Human, primary astrocytes</td>
    <td>(Patel et al. 
     <xref ref-type="bibr" rid="CR384">2019</xref>)
    </td>
   </tr>
   <tr>
    <td colspan="7">HIV-1 strain differences</td>
   </tr>
   <tr>
    <td rowspan="2">Neuronal Survival</td>
    <td>Tat
     <sub>1–86</sub> (clades B &amp; C)
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↓ Neuronal survival via MOR on mixed glia</p>
     <p>• ↑ ROS in astrocytes</p>
     <p>• ↑ Iba1 and 3-NT microglia with morphine</p>
    </td>
    <td>Mouse, primary neurons and mixed glia</td>
    <td>(Zou et al. 
     <xref ref-type="bibr" rid="CR560">2011</xref>)
    </td>
   </tr>
   <tr>
    <td>
     <p>• gp120
      <sub>IIIB</sub>
     </p>
     <p>• gp120
      <sub>MN</sub> (X4)
     </p>
     <p>• gp120
      <sub>ADA</sub> (R5)
     </p>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>↓ Neuronal survival in presence of glia with gp120
     <sub>MN</sub> and transiently with gp120
     <sub>IIIB</sub> (X4), not R5-tropic gp120, in combination with morphine
    </td>
    <td>Mouse, primary neurons and mixed glia</td>
    <td>(Podhaizer et al. 
     <xref ref-type="bibr" rid="CR402">2012</xref>)
    </td>
   </tr>
   <tr>
    <td>Proliferation and maturational fate of neural progenitors and oligodendroglia</td>
    <td>
     <p>• HIV
      <sub>SF162</sub> (R5)
     </p>
     <p>• HIV
      <sub>IIIB</sub> (X4)
     </p>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• ↓ Proliferation of immature neural and OL progenitors with Tat + morphine</p>
     <p>• ↓ NPC DNA synthesis with R5-tropic HIV + morphine</p>
     <p>• ↑ NPC DNA synthesis with X4-tropic HIV + morphine</p>
    </td>
    <td>Mouse, Tat tg; Mouse, Human, primary neural progenitors</td>
    <td>(Hahn et al. 
     <xref ref-type="bibr" rid="CR199">2012</xref>)
    </td>
   </tr>
   <tr>
    <td>GABA function</td>
    <td>
     <p>• HIV
      <sub>BaL</sub> (R5)
     </p>
     <p>• gp120 
      <sub>(ADA, MN, and IIIB)</sub>
     </p>
     <p>• Tat
      <sub>1–86</sub>
     </p>
    </td>
    <td>No</td>
    <td>Morphine</td>
    <td>
     <p>• Tat or morphine ↓ KCC2 levels via CCR5</p>
     <p>• ↑ KCC2 prevents Tat and R5 HIV, gp120, but not X4, gp120 neurotoxicity ± morphine</p>
    </td>
    <td>Human, primary neurons, hNPCs</td>
    <td>(Barbour et al. 
     <xref ref-type="bibr" rid="CR30">2020</xref>)
    </td>
   </tr>
   <tr>
    <td>Astroglial CCL5 and neuroprotection</td>
    <td>
     <p>• gp120
      <sub>IIIB</sub> (X4)
     </p>
     <p>• gp120
      <sub>BaL</sub> (R5)
     </p>
    </td>
    <td>No</td>
    <td>
     <p>• Morphine (10 μM)</p>
     <p>• DAMGO</p>
    </td>
    <td>
     <p>• Morphine ↑ astroglial CCL5 blocking gp120
      <sub>BaL</sub> neurotoxicity
     </p>
     <p>• Morphine (or CXCL12) does not block gp120
      <sub>IIIB</sub> neurotoxicity
     </p>
    </td>
    <td>Rat, mixed neurons and glia; isolated neurons, astrocytes and microglia</td>
    <td>(Avdoshina et al. 
     <xref ref-type="bibr" rid="CR21">2010</xref>)
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <sup>a</sup>assumed Clade B, unless noted otherwise, 
   <sup>b</sup> statistical findings for some results are unclear
  </p>
  <p>
   <italic>ARV</italic>, antiretroviral(s); 
   <italic>BMVEC</italic>, brain vascular endothelial cells; 
   <italic>[Ca</italic>
   <sup>
    <italic>2+</italic>
   </sup>
   <italic>]</italic>
   <sub>i</sub> intracellular calcium concentration; 
   <italic>8-CAC</italic>, 8-carboxamidocyclazocine; 
   <italic>DAMGO</italic>, D-Ala
   <sup>2</sup>, N-MePhe
   <sup>4</sup>, Gly-ol]-enkephalin; 
   <italic>DCF</italic>, dihydro-dichlorofluorescein; 
   <italic>DOR</italic>, δ-opioid receptor; 
   <italic>DHE</italic>, dihydroethidium; 
   <italic>DTG</italic>, dolutegravir; 
   <italic>DPDPE</italic>, [D-Pen
   <sup>2</sup>,D-Pen
   <sup>5</sup>]enkephalin; 
   <italic>FTC</italic>, emtricitabine; 
   <italic>GABA</italic>, γ-aminobutyric acid; 
   <italic>Iba1</italic>, ionized calcium-binding adapter molecule 1; 
   <italic>JAM-1</italic>, junctional adhesion molecule-1; 
   <italic>KCC2</italic>, K
   <sup>+</sup>-Cl
   <sup>−</sup> cotransporter 2; 
   <italic>KOR</italic>, κ-opioid receptor; 
   <italic>LTR</italic>, long terminal repeat; 
   <italic>Δ</italic>
   <sub>
    <italic>Ψm</italic>
   </sub>, mitochondrial inner membrane potential; 
   <italic>MOR</italic>, μ-opioid receptor; 
   <italic>[Na</italic>
   <sup>
    <italic>+</italic>
   </sup>
   <italic>]</italic>
   <sub>i</sub>, intracellular sodium concentration; 
   <italic>nor-BNI</italic>, nor-binaltorphimine; 
   <italic>NPCs</italic>, neural progenitor cells; 
   <italic>OLs</italic>, oligodendroglia; 
   <italic>ROS</italic>, reactive oxygen species; 
   <italic>TEER</italic>, transendothelial electrical resistance; 
   <italic>TFV</italic>, tenofovir; 
   <italic>TUNEL</italic>, terminal deoxynucleotidyl transferase dUTP nick end labeling; 
   <italic>ZDV</italic>, zidovudine
  </p>
  <p>For practicality, the table is limited to key studies in the CNS with emphasis on neuropathological or neuroimmune rather than psychosocial outcomes. With deference toward the excellent studies we excluded: (1) on opioid and HIV effects on PBMCs, or on isolated lymphocytes and monocytes, not directly related to the central nervous system or BBB; (2) on HIV or opioid and ARV interactions in the peripheral nervous system; and (3) studies not directly examining opioid-HIV interactions (irrespective of whether a positive or negative interaction was found)</p>
 </table-wrap-foot>
</table-wrap>
